The evolution of therapeutic modalities drives the adoption of single-use technologies.

Review of SUT Adoption in Biopharma Manufacturing

Despite its understandable hesitancy, the pharma industry is facing a need for more widespread adoption of cloud-based solutions.

Why Are Pharmaceutical Companies Reluctant to Adopt Cloud Technologies?

Given the criticality of fill/finish processes, it is clear that automation is the next technological step.

 Automating the Future of Fill/Finish

Topic

Articles

Key areas to invest include manufacturing process improvements, quality management, and AI.

CPHI Experts Report that Small to Mid-sized US CDMOs Must Invest Now to Benefit from 2025 Contract Funding Surge

Feliza Mirasol is the science editor for 

Podcasts

In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.

Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines

The non-profit initiative puts collaboration at the forefront as it tackles the challenges surrounding recycling primary pharmaceutical packaging.

UK Launches Circularity in Primary Pharmaceutical Packaging Accelerator Initiative to Implement Pharmaceutical Packaging Strategies

SK pharmteco, a CDMO, will manufacture, test, and release Adstiladrin (nadofaragene firadenovec-vncg), a gene therapy from Ferring Pharmaceuticals for treating bladder cancer.

SK pharmteco to Ensure Supply of Ferring Pharmaceuticals Gene Therapy

The collaboration will combine N4’s nanoparticle delivery system with SRI’s molecular guidance system.

N4 Pharma and SRI to Collaborate on Intracellular Delivery to Specific Target Cells

Scott Billman is vice president Global Engineering, Real Estate, and Facilities, at Solventum.

As breakthrough therapeutics in the pharma pipeline approach commercialization, pharmaceutical manufacturing facilities must evolve to meet demand.

Facilities of the Future: Meeting the Demands of Breakthrough Therapeutics

Chris Spivey is director of Industry Relations and Strategic Partnership, MJH Life Sciences.

A tidal wave of questions floats the need for more upstream automation.

The Making of mRNA

Cynthia A. Challener is a contributing editor to Pharmaceutical Technology.

Developing freeze-drying processes requires patience and deep product and process understanding.

Increasing mRNA Product Stability with Lyophilization

In a new agreement, Cellares will utilize its Cell Shuttle fully automated cell therapy manufacturing platform to manufacture select CAR-T cell therapies under development by Bristol Myers Squibb. 

Bristol Myers Squibb to Access Cellares' Cell Therapy Manufacturing Platform in New $380 Million CAR-T Cell Therapy Deal

A panel of experts went over new regulatory requirements for contamination control and gave guidance on implementing a contamination control strategy in cell and gene therapy facilities at INTERPHEX 2024.